Tofacitinib

VANCOUVER, British Columbia — Patients with ulcerative colitis were more likely to achieve clinical response and steroid-free clinical remission at 8 to 16 weeks on upadacitinib vs. ustekinumab, according to a presenter.

Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.

All patients with moderate to severe ulcerative colitis in the tofacitinib OCTAVE UC clinical program who underwent colectomy had prior tumor necrosis factor inhibitor failure and most had additional risk factors, according to analysis.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent how to choose the right ulcerative colitis treatment for the right patient.

DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.

A slew of recent clinical trials and the continued development of new treatments have ensured that the state of rheumatoid arthritis treatment is more advanced than ever before.

Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology.

PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.

PHILADELPHIA — There is “no clear increased risk” for major adverse cardiovascular events associated with tofacitinib, according to a post-hoc analysis of the ORAL Surveillance trial presented at ACR Convergence 2022.